Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
CD8+ T cell metabolism in infection and cancer
M Reina-Campos, NE Scharping… - Nature Reviews …, 2021 - nature.com
Cytotoxic CD8+ T cells play a key role in the elimination of intracellular infections and
malignant cells and can provide long-term protective immunity. In the response to infection …
malignant cells and can provide long-term protective immunity. In the response to infection …
Metabolism of immune cells in cancer
RD Leone, JD Powell - Nature reviews cancer, 2020 - nature.com
Through the successes of checkpoint blockade and adoptive cellular therapy,
immunotherapy has become an established treatment modality for cancer. Cellular …
immunotherapy has become an established treatment modality for cancer. Cellular …
Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells
Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has achieved tremendous
success treating B cell malignancies; however, some patients fail to respond due to poor …
success treating B cell malignancies; however, some patients fail to respond due to poor …
Next-generation CAR T-cell therapies
RM Young, NW Engel, U Uslu, N Wellhausen, CH June - Cancer discovery, 2022 - AACR
CD19-and B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
cells have enabled unprecedented responses in a subset of refractory patients with B-cell …
Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
MD Jain, H Zhao, X Wang, R Atkins… - Blood, The Journal …, 2021 - ashpublications.org
Axicabtagene ciloleucel (axi-cel) is a chimeric antigen receptor (CAR) T-cell therapy for
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …
relapsed or refractory large B-cell lymphoma (LBCL). This study evaluated whether immune …
[HTML][HTML] Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment
NK cells are central to anti-tumor immunity and recently showed efficacy for treating
hematologic malignancies. However, their dysfunction in the hostile tumor microenvironment …
hematologic malignancies. However, their dysfunction in the hostile tumor microenvironment …
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
N Philipp, M Kazerani, A Nicholls, B Vick… - Blood, The Journal …, 2022 - ashpublications.org
T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with
hematologic malignancies; however, resistance and subsequent relapse remains a major …
hematologic malignancies; however, resistance and subsequent relapse remains a major …
BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion
Chimeric antigen receptor (CAR) T cells have not induced meaningful clinical responses in
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
solid tumors. Loss of T cell stemness, poor expansion capacity, and exhaustion during …
Mechanisms of resistance to chimeric antigen receptor-T cells in haematological Malignancies
Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …